Finvest
RPRX Biopharma royalties · Biotech funding · Royalties · Cash flow · Thesis updated June 12, 2026

Drug royalties are compounding, with real debt costs

01 Running thesis

Cash growth, with a longer dispute

Royalty Pharma is built to collect slices of drug sales. Q1 2026 made that model look healthy. Management said recurring royalty receipts grew 13%, and the 10-Q showed Royalty Receipts up 12.5% from last year. The company also raised full-year 2026 Portfolio Receipts guidance to a range of $3.325 billion to $3.45 billion.

The bigger long-term update was daraxonrasib. Revolution Medicines reported Phase III data in second-line pancreatic cancer where the drug nearly doubled overall survival, from just under 7 months with chemotherapy to over 13 months. Royalty Pharma sees this as a major de-risking event for a pipeline asset that could produce more than $300 million in peak annual royalties.

The bear case did not go away. Interest expense rose 43.6% in Q1 2026, and management previously guided to around $350 million to $360 million of interest paid in 2026. The Vertex Alyftrek royalty dispute also now looks like a mid-2027 event, which keeps a key cystic fibrosis cash flow under a cloud for longer.

May 2026▲Q1 2026 strengthened the bull case. Recurring royalty receipts grew 13%, full-year 2026 Portfolio Receipts guidance was raised, and daraxonrasib Phase III data nearly doubled overall survival.
May 2026→The 10-Q confirmed both sides of the story. Royalty Receipts rose 12.5%, but interest expense rose 43.6% and Tazverik led to a $69.4 million impairment.
Feb 2026→Management guided to 3% to 8% Royalty Receipts growth for 2026 and about $350 million to $360 million of interest paid. The growth plan stayed intact, but the debt cost became clearer.
Feb 2026▼The 2025 10-K raised the visibility of two risks: the Vertex Alyftrek dispute and IRA drug pricing pressure. It also showed heavy capital use, including $2.6 billion deployed and $1.2 billion spent on buybacks in 2025.
Nov 2025▲Management raised 2025 Portfolio Receipts guidance to 14% to 16% growth. The company also showed strong capital deployment, including large Imdelltra and Amvuttra royalty buys.
Aug 2025▲Royalty Pharma raised 2025 guidance and announced a Revolution Medicines funding deal of up to $2 billion tied to daraxonrasib. That deal became a major proof point for synthetic royalties.
02 Business model

A bank for drug royalties

Royalty Pharma does not usually discover or sell drugs itself. It buys the right to receive payments tied to drug sales. A royalty is a small cut of revenue from a product, usually paid by the company that markets the drug.

This gives Royalty Pharma exposure to blockbuster medicines without paying for drug sales teams or most lab work. The tradeoff is that it must be good at judging which drugs will last, which patents matter, and which partners will pay on time.

A growing part of the model is synthetic royalties and R&D co-funding. In plain English, Royalty Pharma gives money to a drug company now, often for trials, and gets future sales-based payments if the drug works. The 2025 internalization also removed the old 6.5% management fee on portfolio receipts, which should save cash over time.

03 Product portfolio

The drugs that matter

Cash cow

Cystic fibrosis franchise

This Vertex-linked franchise includes Kalydeco, Orkambi, Symdeko/Symkevi, Trikafta/Kaftrio and Alyftrek. It produced $253.3 million of Q1 2026 Royalty Receipts, but Alyftrek is also tied to the current Vertex dispute.

Growth engine

Evrysdi

Evrysdi treats spinal muscular atrophy and is marketed by Roche. Q1 2026 Royalty Receipts were $79.7 million, up 51.3% from the prior year period.

Growth engine

Tremfya

Tremfya is a Johnson & Johnson immunology drug. Q1 2026 Royalty Receipts were $64.0 million, up 79.5%, helped by market growth and newer inflammatory bowel disease uses.

Growth engine

Voranigo

Voranigo is an oncology royalty tied to Servier's low-grade glioma drug. Q1 2026 Royalty Receipts rose 139.7% to $46.8 million, driven by a strong U.S. launch.

Option

Daraxonrasib

Daraxonrasib is not yet a commercial cash cow, but it is one of the biggest pipeline assets. Phase III data in pancreatic cancer nearly doubled overall survival, and management sees peak annual royalty potential of more than $300 million.

Option

Ziihera and Avlayah

Royalty Pharma recently bought a Ziihera royalty for $250 million and an Avlayah royalty for $200 million. These deals show the company is still putting new capital to work in approved or near-approved medicines.

04 Business segments

Q1 receipt mix

Cystic fibrosis franchise27%modest
Trelegy11%modest
Evrysdi9%growing fast
Tremfya7%growing fast
Voranigo5%growing fast
Other royalty products37%modest
Milestones and other contractual receipts4%declining

Royalty Pharma reports one operating segment. The mix below uses Q1 2026 Portfolio Receipts lines from the 10-Q, not formal business segments, and Vertex was 34% of total income and other revenues.

05 Risk factors

What could break the thesis

Vertex Alyftrek royalty dispute

High impact · Medium odds

Royalty Pharma says that since the second quarter of 2025 it has not received the full Alyftrek royalties it believes it is owed. Management now points to mid-2027 for resolution. A bad outcome would lower a valuable cystic fibrosis cash stream and weaken trust in contract enforceability.

We watchWatch for arbitration updates, any settlement terms, and quarterly cystic fibrosis franchise receipts.

Pipeline or approval failure

High impact · Medium odds

Some royalties depend on drugs that still need trial success or regulatory approval. The upside from daraxonrasib, litifilimab, pelacarsen and other candidates can disappear if data disappoints. The Tazverik withdrawal and $69.4 million impairment in Q1 2026 show that drug-specific failures can still hit the portfolio.

We watchWatch pivotal trial readouts, FDA decisions, and any new impairments in the financial royalty asset table.

Patent loss and competition

High impact · High odds

Royalties fade when drugs face generics, biosimilars, or stronger branded rivals. In Q1 2026, Promacta Royalty Receipts fell 61.1%, and Imbruvica fell 17.3%. Royalty Pharma needs new deals and growing drugs to more than offset these natural declines.

We watchWatch product-level Royalty Receipts, generic launch dates, and patent-expiration disclosures.

Debt and interest drag

Medium impact · Medium odds

Royalty Pharma uses debt to buy more royalties. That can help returns, but it also raises fixed costs. Interest expense rose 43.6% in Q1 2026 after new debt and the term loan assumed in the internalization.

We watchWatch interest paid, total borrowings, credit ratings, and covenant ratios in the liquidity section.

Drug pricing reform

Medium impact · Medium odds

The Inflation Reduction Act lets Medicare negotiate prices for selected drugs. Royalty Pharma does not set drug prices, but its receipts depend on the sales of drugs that other companies sell. If key portfolio drugs face lower prices, royalty receipts could be weaker over time.

We watchWatch CMS Medicare negotiation lists and whether any large Royalty Pharma products are selected.
06 Quick answers

In one breath

What does Royalty Pharma actually do?

It buys the right to collect payments from drug sales. It also funds drug development in exchange for future sales-based payments if the drug succeeds.

Why did Q1 2026 matter for RPRX?

Recurring royalty receipts grew 13%, and management raised full-year 2026 Portfolio Receipts guidance. Daraxonrasib data also made a major pipeline asset look less risky.

What is the Vertex Alyftrek issue?

Royalty Pharma says Vertex has not paid the full royalties it believes are due on Alyftrek. The company now expects the dispute process to run until around mid-2027.

What should investors track most closely?

Track product-level Royalty Receipts, interest paid, new royalty deals, and major clinical readouts. The Vertex dispute and IRA drug pricing rules are also key watch items.